PURE Bioscience Reports $1.25M Net Loss Despite 22% Revenue Growth

PURE Bioscience, Inc. reported its financial results for the six months ended January 31, 2026, revealing a net loss of $1,249,000 on total revenue of $1,152,000. This represents an increase in revenue of approximately 22% compared to the $947,000 reported for the same period in the previous fiscal year. The company's net product sales for the six months reached $1,150,000, up from $946,000 in the prior year, driven primarily by increased sales of its flagship product, PURE® Hard Surface, which accounted for $1,136,000 of total sales. The gross profit for the period was $688,000, yielding a gross margin of 60%, slightly up from 58% in the previous year.

In terms of operational metrics, PURE Bioscience's total current assets decreased to $779,000 as of January 31, 2026, down from $1,047,000 at the end of July 2025. The company’s cash and cash equivalents also fell to $198,000 from $334,000 during the same period. Current liabilities surged to $3,055,000, primarily due to the introduction of convertible notes payable to related parties amounting to $2,139,000. This increase in liabilities contributed to a stockholders' deficiency of $6,273,000, compared to $5,116,000 at the end of the previous fiscal year.

Strategically, the company has focused on expanding its distribution network and enhancing its product offerings. During the reporting period, PURE Bioscience continued to develop its proprietary antimicrobial products based on stabilized ionic silver, with a particular emphasis on food safety applications. The company is actively pursuing partnerships for regulatory approvals to market its products outside the U.S. and is exploring new product development opportunities. The company’s employee headcount remained stable, with no significant changes reported.

Looking ahead, PURE Bioscience faces challenges related to its liquidity and ongoing operational losses. The company has indicated substantial doubt regarding its ability to continue as a going concern, as it has historically relied on financing through equity and debt securities to fund operations. Management has noted that future capital requirements will depend on various factors, including product acceptance, market demand, and the success of its partners in selling its products. The company is committed to addressing these challenges while aiming to achieve sustainable growth through its innovative product lines and strategic partnerships.